All News Items
Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement
03.12.2025 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in South Korea. Eckert & Ziegler will supply SK Biopharmaceuticals with Actinium-225 (Ac-225) to accelerate their research and development activities in radiopharmaceutical therapies. … more
From bench to business
26.11.2025 / What does it take to turn Max Delbrück Center research into a startup? Meet Klaas Yperman, our very first Entrepreneur-in-Residence. Yperman has won a Helmholtz Enterprise grant to develop a roadmap for turning compounds discovered in the Lewin lab into a drug to treat neuropathic pain. … more
Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment
13.11.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales in the first nine months of 2025 by 4% to €224.1 million compared to the same period last year. EBIT before special items from continuing operations (adjusted EBIT) rose by 9% to €50.8 million. Net profit (from continuing and discontinued operations) grew by 28% to €29.9 million, or €0.48 per share. … more
Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma
12.11.2025 / Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient has been dosed in the SANTANA-225 Phase 1/2 study of 225Ac-SSO110 for the treatment of extensive stage small cell lung cancer (ES-SCLC) and Merkle Cell Carcinoma (MCC). 225Ac-SSO110 is a potentially first- and best-in-class Actinium-225-labelled antagonist of the somatostatin type 2 receptor (SSTR2). SSTR2 is highly overexpressed in neuroendocrine tumors relative to healthy tissue, making it an ideal target for radioligand therapies (RLTs). … more
T-knife Therapeutics Presents Preclinical Data
10.11.2025 / T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting … more
Gläsernes Labor: Peering at proteins
10.11.2025 / During project week “Expedition Proteins” at the Gläsernes Labor, students immerse themselves in protein research – isolating samples, loading gels and visiting a real structural biology lab. The week-long workshop gives them a hands-on glimpse into how scientists explore life’s molecular machinery. … more
New developmental disorder discovered: Variations in the UNC13A gene cause neurological impairments in children
10.11.2025 / Problems speaking or walking, muscle tremors, and seizures – in a large interdisciplinary collaboration, researchers led by Noa Lipstein and Nils Brose have discovered a new developmental disorder that can be traced back to variations in the UNC13A gene. The findings not only open up treatment options for those affected, but also offer new insights into other neurological diseases, such as amyotrophic lateral sclerosis (ALS). … more
Ancient viral DNA shapes modern human placentas
05.11.2025 / A collaboration led by Max Delbrück Center and University of Bath has uncovered how ancient viral DNA controls a gene linked to placenta development and pre-eclampsia, a life-threatening pregnancy disorder. The research, published in “Genome Biology,” could help identify pre-eclampsia risk much earlier. … more
Sharks, microbes and a world premiere
27.10.2025 / Berlin Science Week 2025 kicks off on November 1. The Max Delbrück Center invites science enthusiasts to talks and tours, a concert, and exhibitions highlighting our research and to join discussions on a wide range of topics. … more
Why APOE4 raises Alzheimer’s risk
21.10.2025 / Researchers at the Max Delbrück Center and Aarhus University have found a mechanism through which the gene variant APOE4, long linked to a high risk of developing Alzheimer’s disease, impairs neuronal function in the aging brain. The research was published in “Nature Metabolism.” … more
A potential new drug for stiff hearts
17.10.2025 / Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In “Cardiovascular Research,” his group and a US team showed the therapy improves cardiac function in a mouse model of the disease. … more
How malaria harms unborn babies
13.10.2025 / U.K.-based Wellcome has awarded over €2 million to an international research effort to uncover how malaria can injure developing babies. Emanuel Wyler at the Max Delbrück Center will play a key role in studying the molecular interaction between the parasite Plasmodium falciparum and the placenta. … more
Volker Haucke receives the Ernst Schering Prize 2025
23.09.2025 / The Ernst Schering Prize 2025, endowed with 50.000 euros, is awarded to Prof. Dr. Volker Haucke, Director at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Professor of Molecular Pharmacology at Freie Universität Berlin. This prestigious science award honors his groundbreaking discoveries on the function of signaling lipids, which control the cellular responses to messengers, hormones, and nutrients, thereby shaping central processes in cell communication. … more
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
20.09.2025 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, through Novartis Pharma K.K. which will oversee product distribution and safety information management as the Designated Marketing Authorization Holder for GalliaPharm® in Japan. … more
Using deep learning for precision cancer therapy
12.09.2025 / Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in “Nature Communications,” the tool, called Flexynesis, uses deep neural networks and evaluates multi modal data. … more
Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
09.09.2025 / Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price target of € 24.00. This corresponds to a price potential of 46.8% compared to the Xetra closing price of € 16.35 on 8 September 2025. … more
Markus Mittnenzweig wins ERC Starting Grant
05.09.2025 / Markus Mittnenzweig of the Max Delbrück Center has been awarded a €1.5 million grant from the European Research Council. He and his team will build dynamic 3D models of how neighboring cells and gene activity guide early-stage embryonic zebrafish cells to become specialized tissues. … more
Promoting awareness of health research
11.08.2025 / During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Center, Charité – Universitätsmedizin Berlin, the German Center for Child and Adolescent Health and others. … more
Targeting sleeping tumor cells
08.08.2025 / Neuroblastoma, a cancer mainly affecting children, is often difficult to treat. A team led by Jan Dörr and Anton Henssen at the Experimental and Clinical Research Center report in “Cancer Discovery,” a potential reason treatment sometimes fails and a new strategy to combat particularly resistant tumors. … more
How immune cells communicate
07.08.2025 / A team led by Simon Haas has developed a technology to decode how immune cells talk to each other – revealing how our bodies respond to infections, how miscommunication can trigger autoimmune diseases, and why some people don’t respond to immunotherapies. The study was published in “Nature Methods.” … more
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
29.07.2025 / Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 clinical trial of ART-101 in the United States, with manufacturing to be performed at Eckert & Ziegler’s state-of-the-art GMP facility in Boston, MA. … more
Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
28.07.2025 / The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. … more
Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
16.07.2025 / Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023 and from 2023 to 2025. In addition to successfully fulfilling all mandatory criteria, Eckert & Ziegler also scored highly in the voluntary and excellence criteria thanks to its long-standing commitment to training. … more
Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite
15.07.2025 / The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply. … more
Model partnership with NCT Berlin
13.07.2025 / Starting in 2027, Captain T Cell – a Max Delbrück Center biotech spin-off – will begin the first clinical trial of its TCR-T cell therapy. This has been made possible through funding from the National Center for Tumor Diseases and close collaboration with Charité – Universitätsmedizin Berlin. … more
Cutting the environmental impact of research
08.07.2025 / From reducing freezer usage to plastic waste, Max Delbrück Center labs have been implementing strategies from the LEAF program for sustainable research. As more labs join the program, they are not only contributing to reaching our sustainability goals, they are also improving research quality. … more
The cellular engineer
07.07.2025 / Molecular machines carry out many vital processes inside our cells. When their components – protein building blocks – are faulty, it can lead to disease. Structural biologist Oliver Daumke investigates how these machines are built, what makes them work, and what goes wrong when they malfunction. … more
Maike Sander elected member of EMBO
02.07.2025 / The European Molecular Biology Organization has elected Scientific Director of the Max Delbrück Center Maike Sander to its membership. She will join a community of more than 2,100 leading life scientists who guide the organization and help shape the future of life science research. … more
The Long Night of the Sciences 2025
30.06.2025 / The Long Night of the Sciences has been a Berlin tradition for 25 years – and the Max Delbrück Center and Campus Berlin-Buch have been part of it from the very beginning. On June 28, we celebrated this milestone with science enthusiasts, families, and special guests. … more
Biomedical innovation in Berlin gets €30 million boost
26.06.2025 / The Helmholtz Association has approved €30.8 million in funding for the Center for AI–Accelerated Molecular Innovations in Medicine to be located at the Max Delbrück Center. Researchers will use new technologies to develop AI-driven strategies for precision treatment and prevention. … more
Students from Freie Universität Berlin visited the Campus Berlin-Buch
18.06.2025 / Visiting the Campus Berlin-Buch: Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025. … more
Berlin Summer Meeting: Sequencing Planet Earth
13.06.2025 / On June 19 and 20, the 2025 Berlin Institute of Systems Biology of the Max Delbrück Center Summer Meeting will explore how analyzing DNA and RNA can conserve biodiversity, ensure food security, and help detect and prevent disease. … more
Berlin-Buch goes Boston
06.06.2025 / At BIO 2025, June 16-19 in Boston, Campus Berlin-Buch GmbH will be showcasing the location of future innovation Berlin-Buch … more
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
06.06.2025 / Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor. … more
AI helps people and doctors make medical decisions
03.06.2025 / Online symptom checkers often miss the mark. Can AI do better? Researchers from Altuna Akalin’s team at MDC-BIMSB put large language models to the test – evaluating their ability to guide patients and support doctors. Their study was published in “npj Digital Medicine.” … more
Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
30.05.2025 / Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event gathered around 100 decision makers, renowned experts, key partners, and influential industry leaders to explore the transformative potential of radionuclides in precision oncology. … more
Knowledge for your ears
30.05.2025 / The Life Science Learning Lab has launched a new podcast intended to spark young people’s interest in research. During the first three episodes of “scienceCLASH,” students from Berlin interviewed Sarah Kedziora and Theda Bartolomaeus from the ECRC about the gut microbiome’s influence on heart health. … more
First vascularized model of stem cell islet cells
26.05.2025 / Researchers led by Maike Sander, Scientific Director of the Max Delbrück Center, have developed a vascularized organoid model of hormone secreting cells in the pancreas. The advance, published in “Developmental Cell,” promises to improve diabetes research and cell-based therapies. … more
Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
23.05.2025 / Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI), recognize excellently managed medium-sized companies throughout Germany. Eckert & Ziegler has now received this coveted award the second time. … more
Millions in funding for two Clusters of Excellence
23.05.2025 / The Max Delbrück Center is a partner in one newly awarded Berlin based Clusters of Excellence: ImmunoPreCept. NeuroCure has also won another round of funding. All researchers are working toward a common goal – to develop therapies that can intercept diseases on a molecular level. … more
Talk im Cube: International Cooperation and Funding programs in Life Sciences
15.05.2025 / We are excited to continue also in 2025 the Talks in the Cube starting with a further expert discussion focused on International cooperation and Funding programs in Life Sciences. … more
Towards understanding tumors in 3D
02.05.2025 / Researchers in Nikolaus Rajewsky’s lab at Max Delbrück Center combined high-resolution, single-cell spatial technologies to map a tumor’s cellular neighborhoods in 3D and identify potential targets for personalized cancer therapy. They describe their findings in two separate papers in “Cell Systems.” … more
Helmholtz Drug Discovery Conference kommt nach Berlin
24.04.2025 / Vom 28. bis 30. April treffen sich führende Wirkstoffforscher*innen und Unternehmen am Max Delbrück Center. Auf der Helmholtz Drug Discovery Conference 2025 werden sie über RNA-basierte Therapien, PROTACs, KI für die Medikamentenentwicklung und Chemoproteomik diskutieren und neue Kooperationen schmieden. … more
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
24.04.2025 / Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. … more
How the heart and blood vessels influence organs
24.04.2025 / The Helmholtz Institute for Translational AngioCardioScience (HI-TAC) invites attendees to its first Symposium on April 28 and 29, 2025. Researchers from around the world will meet at Heidelberg University to discuss how the heart and blood vessels communicate with the rest of the body to shape health. … more
Consortium of African and European research institutions secures €1.5 million grant to build capacity for early drug discovery in sub-Saharan Africa
23.04.2025 / An African and European research consortium receives €1.5 million from the European Union and additional resources from the Swiss government to support the accumulation of knowledge, skills and innovative capacities for drug discovery in sub-Saharan Africa. The associated project “RAFIKI”, which launched in January 2025, will tackle pressing public health challenges and build new avenues for cooperation between African and European researchers. … more
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
25.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further develop its promising lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. … more
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
20.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing. … more
Inflammatory messenger fuels Alzheimer’s
18.03.2025 / Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer’s disease. The study was published in the journal “Nature Aging.” … more
Events
all events
16.12.2025, 15:00-
16.12.2025, 16:30
Weihnachtliche Führung durch die einzigartige Sammlung historischer Mikroskope auf dem Campus Berlin-Buch
16.12.2025, 16:30-
16.12.2025, 18:00
Christmas tour of the unique collection of historical microscopes on the Campus Berlin-Buch
06.01.2026, 16:00-
06.01.2026, 18:00
Wenn das Immunsystem das Gehirn angreift – Autoimmunerkrankungen des zentralen Nervensystems